A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in Combination With Osimertinib Mesylate Tablets in the Treatment of Recurrent and Metastatic Non- Small Cell Lung Cancer
Latest Information Update: 09 Oct 2025
At a glance
- Drugs Izalontamab (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sichuan Baili Pharmaceutical
Most Recent Events
- 26 Sep 2025 Status changed from recruiting to active, no longer recruiting.
- 18 Sep 2025 Planned End Date changed from 1 Jun 2025 to 1 Dec 2025.
- 18 Sep 2025 Planned primary completion date changed from 1 Jun 2025 to 1 Dec 2025.